Results 31 to 40 of about 38,648 (233)
Integrated results from the COPERNICUS and GALILEO studies. [PDF]
, 2017 OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO.
Ahlers, Christiane +13 more
core +3 more sources
Retinal vascular occlusion in patients with the Covid-19 virus
International Journal of Retina and Vitreous, 2022 Background The coronavirus disease (COVID-19) can cause acute respiratory distress syndrome with dyspnea, anosmia, fever, and cough. Few studies describing ocular findings have been reported.
Helio F. Shiroma +7 more
doaj +1 more source
Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma [PDF]
, 2011 Purpose: To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). Methods: Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (> 21 mm Hg)
Haritoglou, Christos +3 more
core +1 more source
Branch Retinal Vein Occlusion [PDF]
The Journal of Clinical Hypertension, 2003 The most common cause of branch retinal vein occlusion is hypertension. Since retinal arteries and veins share a common adventitial sheath, the thickened artery compresses a retinal vein causing an occlusion, resulting in a retinal hemorrhage. Most patients present in their 60s with unilateral involvement. The patient may be asymptomatic if the macula
Milan R, Patel +2 more
openaire +2 more sources
Central Retinal Vein Occlusion: Etiology, Clinical Presentation and Treatment
Journal of Education, Health and SportIntroduction and Purpose: Retinal vein occlusion (RVO) occurs when the lumen of the retinal vein closes. Central retinal vein occlusion is the second most common retinal vascular disease.
Grzegorz Szcześniak +2 more
doaj +1 more source
F1000Research, 2018 Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care ...
Daniel D. Esmaili, David S. Boyer
doaj +1 more source
Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data [PDF]
, 2014 Retinal vein occlusion (RVO) is a major cause of vision loss. Of the two main types of RVO, branch retinal vein occlusion (BRVO) is 4 to 6 times more prevalent than central retinal vein occlusion (CRVO).
Kolář Petr
core +4 more sources
Fingolimod: therapeutic mechanisms and ocular adverse effects. [PDF]
, 2017 Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms.
A Groves +40 more
core +1 more source
An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy [PDF]
, 2016 AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled.
Carnovale, Anna +7 more
core +1 more source
The new complex method of treatment central retinal veinand branch of retinal vein occlusion
Бюллетень сибирской медицины, 2008 The new treatment method of central retinal vein and branch of retinal vein occlusion, consisting of epiretinal injection of gemasa combined with standard pharmacotherapy was developed.
D. V. Petrachkov
doaj +1 more source